A Houston‑area Rapid Innovation Lab in Webster will test human‑systems mockups for Nyx as The Exploration Co. pushes toward crewed missions to space stations.

Fragments pulled from Arlington Canyon on Santa Rosa Island date to about 13,000 years and bolster a coastal‑migration story of early Americans.

Harvard astrophysicist Avi Loeb will chair a new UAP Science Advisory Council advising a White House UAP board; the group has requested more than 50 Pentagon records.

California's new AI‑unemployment tracker finds no statewide surge, but college‑educated, highly AI‑exposed Bay Area tech workers have seen unemployment claims climb sharply.

San Francisco rolled Copilot out to 30,000 city workers, but adoption is wildly uneven: a few superusers account for much of the activity while many staff barely use it. The gap is forcing new rules and a city AI roadmap.

Allegheny Health Network says Allegheny General Hospital completed the Pittsburgh region’s first robotic-assisted kidney transplant, offering a less-invasive option for select patients.

A $2M construction phase at the historic Cincinnati Observatory will finish a basement overhaul and open more of its 30,000‑item collection to the public.

Bay Area-built FireSat satellites launched Tuesday, promising higher-resolution wildfire detection and faster alerts for firefighters.

Thermo Fisher says the RapidINTEL Plus cartridge is now NDIS‑approved for qualifying crime‑scene samples, letting rapid DNA profiles be searched in CODIS when labs meet FBI standards.

Monarch Fire Protection District has begun carrying blood and plasma on EMS vehicles so paramedics can start life‑saving transfusions at emergency scenes.

UF field tests suggest routine fungicide sprays can loft bacterial spot across tomato rows, prompting UF/IFAS trials of new sprayer setups and timing.

Atrium Health agreed to a $1.8M settlement after lawsuits alleged tracking pixels sent patient portal activity to ad platforms. Eligible users can file claims by Sept. 28, 2026.

Vertex will buy Crinetics for about $10 billion, adding an FDA‑approved oral acromegaly drug and a late‑stage CAH candidate. The deal is expected to close in Q3 2026.